Immunologic correlates of protection induced by vaccination

Pediatric Infectious Disease Journal

Volumn 20, Issue 1, 2001, Pages 63-75

  Plotkin, Stanley A ^a,b  

^a Aventis Pasteur   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antibodies; Cellular responses; Immunology; Protection; Vaccines

Indexed keywords

VACCINE;

ANTIBODY BLOOD LEVEL; CELLULAR IMMUNITY; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNE SYSTEM; MUCOSAL IMMUNITY; PRIORITY JOURNAL; REVIEW; VACCINATION;

ANTIBODIES; HUMANS; IMMUNITY; IMMUNIZATION; INFECTION CONTROL; TREATMENT OUTCOME; VACCINES;

EID: 0035155744     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200101000-00013     Document Type: Review

References (140)

1. Immunological correlates for efficacy of combination vaccines
2. + T lymphocyte responses in experimental viral vaccine studies
3. The induction of mucosal protection by parenteral immunization
4. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines
5. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge
6. Vaccination against the major infectious diseases
7. The prophylactic dose of homologous tetanus antitoxin
8. Passive-active immunization with tetanus immune globulin (human)
9. Circulating antitoxin at the onset of diphtheria in 425 patients
10. Antitoxin antibody levels and the outcome of illness during an outbreak of diphtheria among alcoholics
11. Neonatal tetanus despite immunization and protective antitoxin antibody
12. Specific prophylaxis of tetanus
13. Tetanus
14. Relationship between structure and neutralizing activity of rabbit tetanus antibodies elicited by acellular and whole-cell pertussis DTP vaccines
15. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant
16. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium
17. A correlate of protection for Lymerix(TM) (The Lyme Disease Vaccine)
18. Passive immunization against hepatitis A
19. Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin
20. Hepatitis A vaccine
21. Six years' follow-up after hepatitis A vaccination
22. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis: IV. Final report of results based on clinical diagnosis
23. Immunization against poliomyelitis: Poliomyelitis infection in immunized chimpanzees
24. Experimental studies on passive immunization against poliomyelitis in chimpanzees following subclinical infection
25. Antigenic properties of rabies virus components
26. Immunoglobulin (IgG) and (IgM) antibody responses to rabies vaccine
27. Rabies
28. Additional reports of failure to respond to treatment after rabies exposure in Thailand
29. Yellow fever vaccine: Direct challenge of monkeys given graded doses of 17D vaccine
30. Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel
31. Control and prevention of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
32. Meningococcal meningitis group A: A successful control of an outbreak by mass vaccination
33. The need for revaccination 10 years after primary pneumococcal vaccination in splenectomized adults
34. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization
35. A new typhoid vaccine composed of the Vi capsular polysaccharide
36. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b
37. Polysaccharide vaccines of Group A Neisseria meningitidis and Haemophilus influenzae type b: A field trial in Finland
38. Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies
39. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin
40. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines
41. Prevention of pneumococcal pneumonia by vaccination
42. Minimum protective serum concentrations of pneumococcal anti-capsular antibodies in infant rats
43. Meningococcal vaccines: Current status and future possibilities
44. Human immunity to the meningococcus: IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers
45. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: A preliminary report
46. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever
47. The acellular pertussis vaccine trials: An interpretation
48. A ten year follow-up after immunization with a two component acellular pertussis vaccine
49. Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussis
50. Overview of recent clinical trials of acellular pertussis vaccines
51. The science and fiction of pertussis vaccines
52. A toxoid vaccine for pertussis as well as diphtheria? Lessons to be relearned
53. A placebo-controlled trial of a pertussis-toxoid vaccine
54. Acellular vaccine efficacy trials
55. Household contact study of Bordetella pertussis infections
56. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses
57. Cell-mediated immune responses to antigens of Bordetella pertussis and protection against pertussis in school children
58. Rubella vaccines
59. Antibody response in serum and nasopharynx after naturally acquired and vaccine-induced infection with rubella virus
60. Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus
61. Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland)
62. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines
63. Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine
64. The pneumococcal vaccine after 15 years of use
65. Pneumococcal vaccine after 15 years of use: Another view
66. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity
67. Protection provided by hepatitis B vaccine in a Yupik Eskimo population: Results of a 10-year study
68. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants
69. Vaccine induced immunologic memory for hepatitis B surface antigen: Implications for policy on booster vaccination
70. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): A final report
71. The prevention of hepatitis B with vaccine: Report of the centers for disease control multi-center efficacy trial among homosexual men
72. In vitro anti-HBs production by individual B cells of responders to hepatitis B vaccine who subsequently lost antibody
73. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen
74. Recombinant DNA hepatitis B vaccination in teenagers: Effect of a booster at 5 1/2 years
75. Duration of immunity after hepatitis B vaccination: Efficacy of low-dose booster vaccine
76. Booster response to recombinant yeast-derived hepatitis B vaccine in vaccinees whose anti-HBs responses were initially elicited by a plasma-derived vaccine
77. Clinical experience with hepatitis B vaccines
78. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
79. Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey
80. High antibody responses to booster doses of either Haemophilus influenzae capsular polysaccharide or conjugate vaccine after primary immunization with conjugate vaccines
81. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine
82. Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: Plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine
83. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster
84. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines
85. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease
86. The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination
87. A high degree of natural immunologic priming to the capsular polysaccharide may not prevent Haemophilus influenzae type b meningitis
88. Functional activity of antibodies elicited by octavalent pneumococcal polysaccharide conjugate vaccines, PncT and PncD
89. Pneumococcal conjugate vaccine induces protective immunity in toddlers
90. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization
91. Live attenuated poliovirus vaccine
92. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: Systemic and local immune responses
93. Inactivated poliovirus vaccine: Past and present experience
94. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children
95. Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine
96. Antirotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections
97. Fecal antibody responses to symptomatic and asymptomatic rotavirus infections
98. Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines
99. Rotavirus-specific cytotoxic T lymphocytes passively protect against gastroenteritis in suckling mice
100. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children
101. Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein
102. Natural or vaccine-induced antibody as a predictor of immunity in the face of natural challenge with influenza viruses
103. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses
104. Prevalence of antibody to current influenza viruses and effect of vaccination on antibody response
105. A comparison of live and inactivated influenza A (H1N1) virus vaccines: 2. Long-term immunity
106. Antibody and cytotoxic T lymphocyte responses of humans to live and inactivated influenza vaccines
107. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine
108. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children
109. Cytotoxic T lymphocyte responses of infants after natural infection or immunization with live cold-recombinant or inactivated influenza A virus vaccine
110. Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis
111. + T cells in immunity to tuberculosis infection
112. Modern vaccines: Mycobacterial diseases
113. A strategy to improve the efficacy of vaccination against tuberculosis and leprosy
114. Recent progress in bacterial vaccines: Tuberculosis
115. The plaque-neutralization test as a measure of prior exposure to measles virus
116. Role of virus strain in conventional and enhanced measles plaque neutralization test
117. Measles antibody: Reevaluation of protective titers
118. The role of secondary vaccine failures in measles outbreaks
119. Antibody responses in serum and nasal secretions of children immunized with inactivated and attenuated measles-virus vaccines
120. Cell-mediated immune responsiveness to measles: Its occurrence as a result of naturally acquired or vaccine-induced infection and in infants of immune mothers
121. Measles and measles immunity in children infected with human immunodeficiency virus
122. Responses to measles immunization in children infected with human immunodeficiency virus
123. Progressive immunodeficiency due to infection with human immunodeficiency virus does not lead to waning immunity to measles in a cohort of homosexual men
124. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal
125. Varicella in children with cancer: Seventy-seven cases
126. Lymphocyte responses to varicella zoster virus in the elderly
127. Prevention of varicella by zoster immune globulin
128. A long-term prospective study of varicella vaccine in healthy children
129. Modified cases of chickenpox after varicella vaccination: Correlation of protection with antibody response
130. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents
131. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine
132. Decline of measles antibody titers after immunization in human immunodeficiency virus-infected children
133. Varicella vaccination: Evidence for frequent reactivation of the vaccine strain in healthy children [In Process Citation]
134. Respiratory syncytial virus infection: Immune response, immunopathogenesis, and treatment
135. Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus
136. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children
137. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level
138. Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines
139. Seroprevalence of antibody against poliovirus in inner-city preschool children: Implications for vaccination policy in the United States
140. + T cells for key functions other than specific antibody production